ISL2 Is a Putative Tumor Suppressor Whose Epigenetic Silencing Reprograms the Metabolism of Pancreatic Cancer

Through in vivo CRISPR screening, scientists discovered islet-2 (ISL2) as a candidate tumor suppressor that modulates aggressive PDAC growth.